Keywords: forest, disappoints, despite, eps, hike, drugmaker, laboratories
Forest disappoints, despite 17% EPS hike
Article | 24 January 2005
US drugmaker Forest Laboratories saw its share price fall 0.9% to $41.79 on January 18, after the company posted third-quarter results for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
